# Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus

> **NCT03502694** · PHASE2 · WITHDRAWN · sponsor: **Janssen Research & Development, LLC**

## Conditions studied

- Metapneumovirus

## Interventions

- **DRUG:** Lumicitabine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03502694
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-11-05
- **Primary completion:** 2019-04-30
- **Final completion:** 2020-10-28
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** sponsor decision
- **Last updated:** 2018-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03502694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03502694, "Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03502694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*